Biogen plunges after rival drug for spinal muscular atrophy shows promise
June 18, 2018 at 12:33 PM EDT
Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.
